A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids

Clinical Therapeutics

Volumn 23, Issue 9, 2001, Pages 1355-1390

  Shahidi, Nasrollah T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Anabolic steroids; Anabolic androgenic steroids; Testosterone

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; 5BETA ANDROSTANOLONE; ALKALINE PHOSPHATASE; ANABOLIC AGENT; ANDROSTANOLONE; ANDROSTENEDIONE; ANDROSTERONE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; BUTADIENE DIEPOXIDE; COMPLEMENT COMPONENT C1S; CREATINE KINASE; ERYTHROPOIETIN; ESTRADIOL; ETIOCHOLANOLONE; KETOTIFEN; LYMPHOCYTE ANTIBODY; MITOMYCIN C; NANDROLONE; NANDROLONE DECANOATE; OXANDROLONE; OXYMETHOLONE; RECOMBINANT ERYTHROPOIETIN; STANOZOLOL; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TESTOSTERONE DERIVATIVE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ALCOHOL LIVER DISEASE; ANGIONEUROTIC EDEMA; APLASTIC ANEMIA; BONE MARROW DEPRESSION; BURN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DOPING; DRUG EFFICACY; DRUG SAFETY; GROWTH RETARDATION; HUMAN; HYPOMANIA; LIVER CARCINOMA; LIVER TOXICITY; MUSCLE ATROPHY; OBSTRUCTIVE JAUNDICE; PELIOSIS HEPATIS; REVIEW; SEXUAL DYSFUNCTION; VIRILIZATION;

EID: 0034811303     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80114-4     Document Type: Article

References (239)

1. Über des testosteron, des kristallisierte männliche hormon aus steerentestes
2. Über androstendion, einen hochwirksamen männlichen pragungsstoff
3. 4- androstenol-(17)-on(3) (Testosteron); un weg zur darstellung des testosterons aus cholesterins (Vorlauf Mitteilung)
4. Über die krystallische herstellung des testikelhormons, testosteron (Androsten-3-on-17-ol)
5. Anabolic steroids and athletics
6. Anabolic steroids are fool's gold
7. Anabolic steroids in athletics: How well do they work and how dangerous are they?
8. Anabolic steroids: A review of the literature
9. Epidemiological and policy issues in the measurement of the long term health effects of anabolic-androgenic steroids
10. Androgenic-anabolic steroid use in adolescents
11. Anabolic steroid use in adolescent athletes
12. Steroids: Breakfast of champions
13. Anabolic steroid abuse
14. Cardiac dysfunction in athletes receiving anabolic steroids
15. Anabolic steroid-induced tendon pathology: A review of the literature
16. Anabolic steroids in the athlete
17. Use and abuse of anabolic and other drugs for athletic enhancement
18. Anabolic steroids: A review of their effects on the muscles, of their possible mechanisms of action and of their use in athletics
19. Anabolic-androgenic steroids and the adolescent
20. Anabolic-androgenic steroids and psychiatric-related effects: A review
21. Anabolic-androgenic steroids and athletes: What are the issues?
22. A review of anabolic steroids: Uses and effects
23. Anabolic-androgenic steroids: Use and abuse
24. Anabolic steroids and growth hormone
25. Weight training. A potential confounding factor in examining the psychological and behavioural effects of anabolic-androgenic steroids
26. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update
27. Steroid abuse in female athletes
28. Issues in detecting abuse of xenobiotic anabolic steroids and testosterone by analysis of athletes' urine
29. Adolescents anabolic steroids: A subject review
30. Anabolic agents
31. Performance enhancing drugs (doping agents) and sudden death - A case report and review of the literature
32. The 5α-reduction of testosterone in the neuroendocrine structures. Biochemical and physiological implications
33. The 5α-reductase in the brain: Molecular aspects and relation to brain function
34. The intranuclear metabolism of testosterone in the accessory organs of reproduction
35. 4-reductase. Their physiological role and significance
36. Sexualhormone X herstellung des 17-methyltestosteron und anderer androsten und androstanderivate. Zusammenhänge zwischen chemischer konstitution und männlicher hormonwirkung
37. Hydroaromatic steroid hormones. 10-Nortestosterone
38. The facile synthesis of 19-nortestosterone and 19-norandrostendione from estrone
39. Urinary metabolites of administered 19-nortestosterone
40. Aromatization of 19-norandrogens by equine testicular microsomes
41. 2-Oxasteroids: A new class of biologically active compounds
42. Oxandrolone disposition and metabolism in man
43. Steroids CV 2-methyl and 2-hydroxymethylene-androstane derivatives
44. Studies on anabolic steroids. GC/MS characterization of unusual seco acidic metabolites of oxymetholone in human urine
45. Studies on anabolic steroids. 10. Synthesis and identification of acidic urinary metabolites of oxymetholone in a human
46. Steroidal-(3,2-c)-pyrazoles
47. Metabolism of stanozolol: Identification and synthesis of urinary metabolites
48. Metabolism of anabolic androgenic steroids
49. The effect of male hormone on the protein and energy metabolism of castrated dogs
50. The relationship of synthetic male hormone, androstenedione, to the protein and energy metabolism of castrate dogs and the protein metabolism of a normal dog
51. Testosterone and testosterone acetate and the protein and energy metabolism of castrate dogs
52. The effect of testosterone propionate on nitrogen, electrolyte, water and energy metabolism in eunuchoidism
53. Definition of androgens and protein anabolic steroids
54. Adverse effects of anabolic steroids
55. Comparative myotrophic and nitrogen retaining effects of several steroids
56. A comparison of the myotropic and androgenic activities of the phenylpropionates and decanoates of testosterone and nandrolone
57. Relative potency of various steroids in an anabolic-androgenic assay using the castrated rat
58. Anabolic activity of 2-oxa- 17α-methyldihydrotestosterone (oxandrolone) in castrated rats
59. Biological actions of androgens
60. Characterization of the androgen receptors in the skeletal muscle of the rat
61. Characterization and quantification of the androgen and glucocorticoid receptors in cytosol from rat skeletal muscle
62. Regulation of the androgen and glucocorticoid receptors in rat and mouse skeletal muscle cytosol
63. Relative binding affinity of anabolicandrogenic steroids: Comparison of the binding to the androgen receptors in skeletal muscle and prostate as well as to sex hormone-binding globulin
64. Modulation of the cytosolic androgen receptor in striated muscle by sex steroids
65. In vitro metabolism of 5α-dihydrotestosterone to 5α-androstane-3α, 17β-3-diol in rat heart, diaphragm, skeletal muscle and bulbocavernous/levator ani: Enzyme characterization and quantification
66. Regulation and compartmentalization of androgens in the rat prostate and muscle
67. Endocrine aspects of anabolic steroids
68. Glucocorticoid antagonism by exercise and androgenic-anabolic steroids
69. Comparison of protein anabolic property of various androgens in the castrated rat
70. A comparative study of the metabolic effects of testosterone propionate in normal men and women and in eunuchoidism
71. Effect of testosterone on muscle mass and muscle protein synthesis
72. Anabolic steroid: Effect on strength development
73. Weight, size, and strength - Unchanged with steroids
74. Effects of an androgenic-anabolic steroid on strength development and plasma testosterone levels in normal males
75. The effects of an anabolic steroid on the strength, body composition, and endurance of college males when accompanied by a weight training program
76. Anabolic steroid effects on body composition in normal young men
77. Influence of methyl testosterone on muscular work and creatine metabolism in normal young men
78. Human strength and endurance responses to anabolic steroid and training
79. Effects of androgenic-anabolic steroids on neuromuscular power and body composition
80. Biochemical and physical effects of an anabolic steroid in competitive swimmers and weightlifters
81. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
82. Testosterone replacement increases fatfree mass and muscle size in hypogonadal men
83. Androgens and erythropoiesis
84. Hormonal factors influencing erythropoiesis
85. The effect of sex hormones on the anemia induced by hemorrhage in the rat
86. Effect of sex hormones on erythrocyte number in the blood of the domestic fowl
87. The effects of castration and cryptorchidization on the blood picture of the golden hamster
88. Effects of castration and sex hormones on blood of the rat
89. Effects of hypophysectomy, castration, and testosterone propionate on hemopoiesis in the adult male rat
90. Influence of age and sex on hemoglobin: A spectrophotometric analysis of nine hundred and nineteen cases
91. Variation of the hemoglobin level with age and sex
92. The cause of the sexual differences in erythrocyte, hemoglobin and serum iron levels in human adults
93. Congenital adrenal hyperplasia associated with polycythemia
94. A note on the effect of certain androgens upon red blood cell count and upon glucose tolerance
95. Increased erythropoiesis induced by androgenic-hormone therapy
96. The role of puberty in red-cell production in hereditary haemolytic anaemias
97. Mechanism of action of androgens on erythropoiesis
98. Further studies on the erythropoietic effect of androgens
99. Use of mild plethora to demonstrate an erythropoietic effect from small amounts of androgens
100. Mechanism of testosterone action in erythropoiesis
101. The erythropoietic-stimulating effects of androgens
102. Inhibition of erythropoietic effects of hormones by erythropoietin antisera in mildly plethoric mice
103. Inhibition of erythropoietic stimulation by testosterone in polycythemic mice receiving anti-erythropoietin
104. Erythropoietin excretion in man following androgens
105. Erythropoietin and erythropoiesis in anemic man following androgens
106. Effects of testosterone on erythropoietin production in isolated perfused kidneys
107. Effects of testosterone and of cobalt on erythropoietin production by anephric rats
108. Further observations on the mechanism by which androgens and growth hormone influence erythropoiesis
109. Effects of large doses of androgen on rodent erythropoiesis and body composition
110. Ribosomes of mouse kidney: Regulation by androgens
111. Oxymetholone treatment for the anemia of bone marrow failure
112. Tissue culture of bone marrow. II. Effect of steroid hormones on hematopoiesis in vitro
113. Effect of steroids on the cycling of haemopoietic stem cells
114. Steroid control of porphyrin and heme biosynthesis: A new biological function of steroid hormone metabolites
115. Stimulation of hemoglobin synthesis in chick blastoderms by certain 5β androstane and 5β pregnane steroids
116. Studies on the control of hemoglobin synthesis: The in vitro stimulating effect of a 5β-H steroid metabolite on heme formation in human bone marrow cells
117. Testosterone and synthetic androgens improve the in vitro survival of human marrow progenitor cells in serum-free suspension cultures
118. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease
119. Effects of testosterone and erythropoietin on erythroid colony formation in human bone marrow cultures
120. Effect of organic and inorganic phosphates on the oxygen equilibrium of human erythrocytes
121. The effect of organic phosphates from the human erythrocyte on the allosteric properties of hemoglobin
122. Androgen-induced increase in red-cell 2,3-diphosphoglycerate
123. The effects of deoxygenation of adult and fetal hemoglobin on the synthesis of red cell 2,3-diphosphoglycerate and its in vivo consequences
124. Effect of a single oral dose of oxymetholone on the metabolism of human erythrocytes
125. The effect of androgen administration on erythrocyte 2,3-diphosphoglycerate level and oxygen affinity in primates
126. Variations of erythrocyte glycolysis following androgens
127. Effect of testosterone propionate on the erythropoietic tissue of three congenital anemias in mice
128. Physiological responses to resistance-exercise in athletes self-administering anabolic steroids
129. Osteoporosis in hypogonadal men: Role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption, and low bone formation
130. Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells
131. High-affinity androgen binding and androgenic regulation of α1(I)-procollagen and transforming growth factor-β steady state messenger ribonucleic acid levels in human osteoblast-like osteosarcoma cells
132. Effects of androgens on parathyroid hormone and interleukin-1-stimulated prostaglandin production in cultured neonatal mouse calvariae
133. Identification of androgen receptors in normal human osteoblast-like cells
134. Androgen receptors in osteoblast-like cell lines
135. Androgens directly stimulate proliferation of bone cells in vitro
136. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism
137. Bone and mineral metabolism in the androgen-resistant (testicular feminized) male rat
138. Effect of excess endogenous androgens on bone density in young women
139. Polycystic ovary syndrome, androgen excess, and the impact on bone
140. Relation between bone mass and muscle weight
141. Direct modulation by androgens of the response of human bone cells (SaOS-2) to human parathyroid hormone (PTH) and PTH-related protein
142. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection
143. Ketotifen in HIV-infected patients: Effects on body weight and release of TNF-alpha
144. Oxandrolone in AIDS-wasting myopathy
145. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection
146. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: A randomized controlled trial
147. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels
148. Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus
149. Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial
150. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients
151. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial
152. Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome
153. Megestrol acetate in patients with ADS-related cachexia
154. Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation
155. Comparison of the anabolic effects and complications of human growth hormone and the testosterone analog, oxandrolone, after severe burn injury
156. The anticatabolic and wound healing effect of the testosterone analog oxandrolone after severe burn injury
157. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: Results of a Department of Veterans Affairs cooperative study
158. Protein energy malnutrition in severe alcoholic hepatitis: Diagnosis and response to treatment
159. Growth promotion by oxandrolone in a girl with short stature and early pubertal development treated with growth hormone and gonadotropin-releasing hormone-analogue. A case study
160. Oxandrolone therapy in constitutionally delayed growth and puberty
161. Growth promotion and Turner-specific bone age after therapy with growth hormone and in combination with oxandrolone: When should therapy be started in Turner syndrome?
162. Combined therapy with growth hormone and oxandrolone in adolescent girls with Turner syndrome
163. Testosterone-induced remission in aplastic anemia
164. Testosterone-induced remission in aplastic anemia of both acquired and congenital types - Further observations in 24 cases
165. Anemias caused by infection and toxins, idiopathic aplastic anemia and anemia caused by renal disease
166. Oxymetholone therapy in aplastic anemia
167. Anabolic androgenic steroids in the treatment of acquired aplastic anemia
168. Oxymetholone treatment in hypoproliferative anemia. I. Frequency of response
169. Immunologic mechanisms in aplastic anemia
170. Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial
171. Effect of androgens on the response to antithymocyte globulin in patients with aplastic anemia
172. Treatment of aplastic anemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: A randomized trial from the EBMT SAA Working Party
173. Androgen dependency in acquired aplastic anemia
174. Treatment of acquired aplastic anemia with cyclosporine and androgens
175. Fanconi anemia, dyskeratosis congenita and WT syndrome
176. Constitutional aplastic anemia
177. The bone marrow failure syndromes
178. Congenital bone marrow failure syndromes: Diagnostic and therapeutic strategies
179. Oxymetholone treatment in myelofibrosis
180. Oxymetholone treatment for sickle cell anemia
181. Hairy cell leukemia. Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients
182. Aplastic anaemia after exposure to burning oil
183. Aplastic anemia complicating systemic lupus erythematosus: Response to androgens in two patients
184. Effect of oxymetholone on human cyclic haematopoiesis
185. Refractory anaemia (RA) type I FAB treated with oxymetholone (OXY): Long-term results
186. Abnormal cytogenetic clones in patients with aplastic anemia: Response to immunosuppressive therapy
187. An eleven-year response of trisomy 8 myelodysplastic syndrome (MDS) to oxymetholone (OXYM)
188. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients
189. Anabolic steroids. Review
190. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. II. Short-term effects on nitrogen metabolism, metabolic balance, and nutrition
191. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function
192. A biochemical abnormality in hereditary angioneurotic edema: Absence of serum inhibitor of C 1-esterase
193. Hereditary and acquired C 1-inhibitor deficiency: Biological and clinical characteristics in 235 patients
194. Hereditary angioedema: A decade of management with stanozolol
195. Long-term treatment of hereditary angioedema with attenuated androgens: Survey of a 13-year experience
196. Clinical and biochemical effects of impeded androgen (oxymetholone) therapy of hereditary angioedema
197. Prophylactic treatment of hereditary angioneurotic edema with anabolic steroids
198. Long-term therapy of hereditary angioedema (HAE). Preventive management with fluoxymesterone and oxymetholone in severely affected males and females
199. Hereditary angioedema
200. Treatment of hereditary protein C deficiency with stanozolol
201. Hemostatic effects of stanozolol in elderly medical patients
202. Protein C, an anticoagulant protein increased in healthy volunteers and surgical patients after treatment with stanozolol
203. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults
204. Protein C antigen levels in major abdominal surgery: Relationships to deep vein thrombosis, malignancy and treatment with stanozolol
205. A double-blind trial of intramuscular stanozolol in the prevention of postoperative deep vein thrombosis following elective abdominal surgery
206. Familial antithrombin III deficiency
207. Oxymetholone therapy in patients with familial antithrombin III deficiency
208. Treatment with stanozolol of type I protein C deficiency in an Italian family
209. Decreased anticoagulant tolerance with oxymetholone
210. Haemostatic effects of supraphysiological levels of testosterone in normal men
211. Decreased anticoagulant tolerance with oxymetholone
212. Drug-induced cholestasis
213. Hepatotoxic effects of the anabolic/androgenic steroids
214. Steroids and other hormones
215. Anabolic steroid-induced hepatotoxicity: Is it overstated?
216. Peliosis hepatis. Twelve cases associated with oral androgen therapy
217. Peliosis hepatis associated with androgenic-anabolic steroid therapy. A severe form of hepatic injury
218. High incidence of peliosis hepatis in autopsy cases of aplastic anemia with special reference to anabolic steroid therapy
219. Analysis of 65 Turkish patients with congenital aplastic anemia (Fanconi anemia and non-Fanconi anemia): Hacettepe experience
220. Peliosis hepatis. Report of a case
221. Reversal of liver damage due to long term methyltestosterone and safety of non-17 α-alkylated androgens
222. Fanconi's anemia and hepatic cirrhosis
223. Hepatocellular carcinoma associated with anabolic steroid therapy: Report of a case and review of the Japanese literature
224. The infectious complications of anabolic-androgenic steroid injection
225. Exuberant local tissue reaction to intramuscular injection of nandrolone decanoate (Deca-Durabolin) - A steroid compound in a sesame seed oil base - Mimicking soft tissue malignant tumors: A case report and review of the literature
226. Use of methyltestosterone to stimulate growth
227. Study of an anabolic steroid. Certain effects of oxymetholone on small children
228. Atherogenic effect of anabolic steroids on serum lipid levels. A literature review
229. The dyslipoproteinemia of anabolic steroid therapy: Increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein2 cholesterol
230. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels
231. High-density-lipoprotein cholesterol in bodybuilders vs powerlifters. Negative effects of androgen use
232. Lipoprotein analysis in bodybuilders
233. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders
234. Glucose intolerance and insulin resistance in aplastic anemia treated with oxymetholone
235. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids
236. Testicular responsiveness to human chorionic gonadotrophin during transient hypogonadotrophic hypogonadism induced by androgenic/anabolic steroids in power athletes
237. Response of serum testosterone and its precursor steroids, SHBG and CBG to anabolic steroid and testosterone self-administration in man
238. Response of serum hormones to androgen administration in power athletes
239. Reversible azoospermia induced by the anabolic steroid 19-nortestosterone